# First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

> **NCT01337154** · PHASE2 · TERMINATED · sponsor: **CytRx** · enrollment: 140 (actual)

## Conditions studied

- Stage IIIB Non-small Cell Lung Cancer With Pleural Effusion
- Stage IV Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Tamibarotene
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01337154
- **Lead sponsor:** CytRx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-04
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 140 (ACTUAL)
- **Why stopped:** Interim analysis showed that the primary endpoint would not be met.
- **Last updated:** 2013-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01337154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01337154, "First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01337154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*